JP2022502358A5 - - Google Patents

Info

Publication number
JP2022502358A5
JP2022502358A5 JP2021514549A JP2021514549A JP2022502358A5 JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5 JP 2021514549 A JP2021514549 A JP 2021514549A JP 2021514549 A JP2021514549 A JP 2021514549A JP 2022502358 A5 JP2022502358 A5 JP 2022502358A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
fragment
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514549A
Other languages
English (en)
Japanese (ja)
Other versions
JP7476174B2 (ja
JP2022502358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/075065 external-priority patent/WO2020058360A1/en
Publication of JP2022502358A publication Critical patent/JP2022502358A/ja
Publication of JP2022502358A5 publication Critical patent/JP2022502358A5/ja
Priority to JP2024067065A priority Critical patent/JP2024102112A/ja
Application granted granted Critical
Publication of JP7476174B2 publication Critical patent/JP7476174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514549A 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Active JP7476174B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067065A JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732863P 2018-09-18 2018-09-18
DE102018122900 2018-09-18
DE102018122900.3 2018-09-18
US62/732,863 2018-09-18
PCT/EP2019/075065 WO2020058360A1 (en) 2018-09-18 2019-09-18 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067065A Division JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Publications (3)

Publication Number Publication Date
JP2022502358A JP2022502358A (ja) 2022-01-11
JP2022502358A5 true JP2022502358A5 (cg-RX-API-DMAC7.html) 2023-06-16
JP7476174B2 JP7476174B2 (ja) 2024-04-30

Family

ID=68062920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514549A Active JP7476174B2 (ja) 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Country Status (19)

Country Link
US (10) US10954281B2 (cg-RX-API-DMAC7.html)
EP (1) EP3852787A1 (cg-RX-API-DMAC7.html)
JP (2) JP7476174B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210063320A (cg-RX-API-DMAC7.html)
CN (1) CN113164569A (cg-RX-API-DMAC7.html)
AU (1) AU2019342860A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003511A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108582A1 (cg-RX-API-DMAC7.html)
CL (3) CL2021000653A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003404A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210141A (cg-RX-API-DMAC7.html)
IL (2) IL309715A (cg-RX-API-DMAC7.html)
MA (1) MA53644A (cg-RX-API-DMAC7.html)
MX (1) MX2021003089A (cg-RX-API-DMAC7.html)
PE (1) PE20211643A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550581A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101926TA (cg-RX-API-DMAC7.html)
TW (1) TW202024121A (cg-RX-API-DMAC7.html)
WO (1) WO2020058360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2021188743A2 (en) * 2020-03-20 2021-09-23 Neo7Logix, Llc Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病(aml)に対する新規の腫瘍特異的抗原及びそれらの使用
CN115843747B (zh) * 2022-12-02 2024-08-20 吉林大学 一种Lama3基因点突变的小鼠模型及其构建方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US11175289B2 (en) * 2016-11-16 2021-11-16 Lei Han Application of TRPM8 protein, related peptide fragment and their antibodies
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子

Similar Documents

Publication Publication Date Title
JP2024041841A5 (cg-RX-API-DMAC7.html)
JP2024099580A5 (cg-RX-API-DMAC7.html)
JP2021535900A5 (cg-RX-API-DMAC7.html)
JP2022502015A5 (cg-RX-API-DMAC7.html)
JP2019511214A5 (cg-RX-API-DMAC7.html)
JP2021168652A5 (cg-RX-API-DMAC7.html)
JP2020516681A5 (cg-RX-API-DMAC7.html)
JP2019502360A5 (cg-RX-API-DMAC7.html)
JP2021514178A5 (cg-RX-API-DMAC7.html)
EP2951202B1 (en) High avidity binding molecules recognizing mage-a1
JP2021528046A5 (cg-RX-API-DMAC7.html)
JP2019510465A5 (cg-RX-API-DMAC7.html)
JP2018510628A5 (cg-RX-API-DMAC7.html)
JP2020191862A5 (cg-RX-API-DMAC7.html)
JP2020182458A5 (cg-RX-API-DMAC7.html)
JP2020198875A5 (cg-RX-API-DMAC7.html)
JP2018529320A5 (cg-RX-API-DMAC7.html)
JP2019506838A5 (cg-RX-API-DMAC7.html)
JP2019516663A5 (cg-RX-API-DMAC7.html)
JP2018536383A5 (cg-RX-API-DMAC7.html)
JP2018520653A5 (cg-RX-API-DMAC7.html)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018509135A5 (cg-RX-API-DMAC7.html)
JP2018518937A5 (cg-RX-API-DMAC7.html)
JP2018519243A5 (cg-RX-API-DMAC7.html)